Sarepta cuts 36% of workforce, expects $400M in annual savings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
July 16, 2025 4:01 PM EDTAfter strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets
Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees
Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025
U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population... More
